<DOC>
	<DOCNO>NCT02670564</DOCNO>
	<brief_summary>Pharmacogenomics ( PG ) offer opportunity individualize treatment accord patient genetic variation influence activity enzyme metabolize act pathway prescribe chemotherapy drug . This add-on research aim prospectively investigate variation several candidate gene relate type chemotherapeutic drug TBI use main related study NCT 01949129 , THE ALL SCTped FORUM study potential role predictive biomarkers PK variability outcome myeloablative therapy pediatric patient receive allogeneic hematopoietic stem cell transplantation acute lymphoblastic leukemia .</brief_summary>
	<brief_title>ALL SCTped FORUM - Pharmacogenomic Study ( add-on Study )</brief_title>
	<detailed_description>Note add-on study NCT 01949129 , THE ALL SCTped FORUM study . Please refer main study detail . Busulfan ( Bu ) key compound condition myeloablative regimen patient undergo hematopoietic stem cell transplantation ( HSCT ) . Bu long use treatment patient leukemia congenital disorder ; advantage disadvantage treatment well describe . However , although Bu treatment show effective , use may limit related adverse event veno-occlusive disease ( VOD ) , interstitial pneumonitis , acute Graft v Host Disease ( GVHD ) , seizures . Thus , novel therapy investigate well pharmacogenetics drug . One alternative drug may replace Bu due low toxicity profile Treosulfan ( Treo ) . Fludarabine ( Flu ) usually use combination Bu Treo alternative cyclophosphamide ( Cy ) also due low toxicity . Thus , Bu/Flu regimen use often previously common Bu/Cy regimen . However , improvement regimen still need reduce adverse drug effect . Pharmacogenomics ( PG ) offer opportunity individualize treatment accord patient genetic variation influence activity enzyme metabolize act pathway prescribe chemotherapy drug . This add-on research aim prospectively investigate variation several candidate gene ( e.g GST , DCK DNA repair pathway gene ) relate type chemotherapeutic drug ( Bu/Flu/Thio ; Treo/Flu/Thio TBI/VP16 ) use protocol potential role predictive biomarkers pharmacokinetics ( PK ) variability outcome myeloablative therapy pediatric patient receive allogeneic HSCT acute lymphoblastic leukemia For busulfan arm country : cross-validation busulfan quantification perform . All Bu Therapeutic Drug Monitoring participate main ALL SCTped FORUM study assess accuracy ( % ) trueness ( % ) 8 blind Bu Quality Control sample . Criteria acceptance set accord FDA ICH guideline . Blood sample collect prior initiation therapy DNA banking DNA analysis ( patient ) , DNA analysis ( TBI/VP16 , Bu/Flu/Thiotepa Treo/Flu/Thiotepa group ) PK analysis ( Bu group ) . PK pharmacogenomic data correlate studied outcome ( e.g.Veno-occlusive disease , Graft vs host disease , Treatment Related Mortality , Events Free Survival , Overall Survival ) . Recruitment : Patients ( child ) age 0-18 recruited arm . No oral Bu allow study . Shipment ( minimum 10 patient ) Send material list : Dr Marc Ansari , Plateforme d'Hématologie et Oncologie Pédiatrique ( CANSEARCH research laboratory ) , Faculté de Médecine , Bâtiment Tulipe , 5th floor , Av De La Roseraie 64 , GENEVE 1205 Switzerland . Contact Dr. Ansari 's laboratory prior shipment : Phone ( +41 79 55 36 100 ) e-mail ( research @ cansearch.ch ) . All shipment must send frozen carrier guarantee overnight delivery indication `` Pharmacogenomic study '' face parcel .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Treosulfan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Note addon study NCT 01949129 , THE ALL SCTped FORUM study . Please refer main study detail . Gender Both : female male participant study Age Limits Minimum Age : N/A Maximum Age : age time screen less 18 year old Accepts Healthy Volunteers : Eligibility Criteria Patients ALL ( except patient BALL ) indication allogeneic HSCT complete remission ( CR ) HSCT write consent parent ( legal guardian ) , necessary , minor patient via `` Informed Consent Form '' pregnancy secondary malignancy previous HSCT HSCT perform study participate centre Non HodgkinLymphoma ALL extramedullary involvement indication TBI CNS involvement timepoint screen Trisomy 21 The whole protocol essential part decline either patient himself/herself respective legal guardian No consent give save propagation anonymous medical data study reason Severe concomitant disease allow treatment accord protocol investigator 's discretion ( e.g . malformation syndrome , cardiac malformation , metabolic disorder ) Karnofsky / Lansky score &lt; 50 % Subjects unwilling unable comply study procedure</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>pharmacogenetics</keyword>
	<keyword>busulfan</keyword>
	<keyword>treosulfan</keyword>
	<keyword>hematopoietic stem cell transplantation</keyword>
	<keyword>fludarabine</keyword>
	<keyword>pediatric patient</keyword>
	<keyword>TBI</keyword>
	<keyword>leukemia</keyword>
	<keyword>leukemia , lymphoid</keyword>
	<keyword>precursor cell lymphoblastic Leukemia-Lymphoma</keyword>
	<keyword>Immune System disease</keyword>
	<keyword>Immunoproliferative Disorders</keyword>
	<keyword>stem cell transplantation</keyword>
	<keyword>child adolescent</keyword>
	<keyword>high risk acute lymphoblastic leukemia</keyword>
	<keyword>NCT01949129 add-on</keyword>
	<keyword>ALL SCTped FORUM</keyword>
</DOC>